Endocrine therapy resistance (ETR) in hormone receptor-positive, HER2-negative metastatic breast cancer (HR+, HER2-mBC): Prevalence, biomarker characteristics, and outcomes.

被引：0

作者：

Jeselsohn, Rinath

Chen, Lu

Chaudhary, Nayan

Martinalbo, Jorge

Fasching, Peter A.

Hafner, Marc

Luhn, Patricia

Montero, Alberto J.

Perez-Moreno, Pablo Diego

Wander, Seth Andrew

Kalinsky, Kevin

机构：

[1] Dana Farber Canc Inst, Boston, MA USA

[2] Genentech Inc, South San Francisco, CA USA

[3] F Hoffmann La Roche Ltd, Basel, Switzerland

[4] Univ Hosp Erlangen, Dept Obstet & Gynecol, Erlangen, Germany

[5] Univ Hosp Seidman Canc Ctr, Cleveland, OH USA

[6] Massachusetts Gen Hosp, Boston, MA USA

[7] Winship Canc Inst, Atlanta, GA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1062

引用

页数：1